CRISPR Therapeutics AG (CRSP) Receivables (2015 - 2024)

CRISPR Therapeutics AG has disclosed Receivables across 10 years of filings, most recently posting $27.1 million for Q4 2024.

• In Q4 2024, Receivables fell 86.88% year-over-year to $27.1 million; the TTM figure through Dec 2024 stood at $27.1 million (down 86.88% YoY), while the FY2024 annual figure was $27.1 million, down 86.88% from the prior year.
• Receivables came in at $27.1 million for Q4 2024 at CRISPR Therapeutics AG, down from $206.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $206.5 million in Q4 2023 to a low of $49000.0 in Q3 2022.
• Average Receivables over 5 years is $29.0 million, with a median of $10.8 million recorded in 2020.
• Year-over-year, Receivables sank 99.7% in 2021 and surged 105960.61% in 2023.
• Over 5 years, Receivables stood at $10.8 million in 2020, then decreased by 19.73% to $8.7 million in 2021, then advanced by 28.66% to $11.2 million in 2022, then jumped by 1743.75% to $206.5 million in 2023, then sank by 86.88% to $27.1 million in 2024.
• Per Business Quant data, the three most recent Receivables figures were $27.1 million in Q4 2024, $206.5 million in Q4 2023, and $70.0 million in Q2 2023.